Innovative Partnership for Veterinary and Human Health
Pioneering Research Will Help Drive Dual-Purpose Treatment for Life-Threatening Conditions in Both Humans and Dogs
Lamassu Biotech is excited to announce a collaboration with The Ohio State University aimed at advancing a new treatment for acute pancreatitis, a serious condition affecting both humans and man's best friend. The partnership is dedicated to developing RABI-767, a unique therapeutic solution that targets acute pancreatitis—an ailment that currently has no effective treatments.
Understanding Acute Pancreatitis
Acute pancreatitis is a serious health issue that results in hundreds of thousands of hospital admissions each year. This condition affects many individuals and a staggering number of dogs, indicating a significant need for effective treatment solutions. The collaboration between Lamassu Biotech and The Ohio State University aims to create a bridge between human and veterinary medicine. Understanding how to treat this condition in dogs can ultimately lead to advancements in treatment options for humans, creating a win-win situation.
Research Initiatives for Both Species
The collaboration is strategically designed to explore various dosing schedules for RABI-767 through veterinary studies. These evaluations will assess how well the drug manages pancreatitis in canines, with trials set to commence shortly. This research holds promise not only for improving outcomes in dogs but also for enhancing understanding of the disease in human patients.
Expert Insights on the Collaboration
Dr. Gabi Hanna, CEO and founder of Lamassu Biotech, commented on the significance of this undertaking: "This is an exciting development for those suffering from acute pancreatitis and for our four-legged family members who might also be impacted by this life-threatening condition. By working with Ohio State, we are advancing research that has the potential to help both dogs and people. The data we collect from the canine trials will help accelerate the development of human applications."
Clinical Trials and Future Impacts
The collaboration will facilitate companion clinical trials at Ohio State's College of Veterinary Medicine. The trials will investigate the efficacy of RABI-767 in treating spontaneous canine acute pancreatitis (CAP). The outcomes of these trials are expected to yield vital information that could refine dosing strategies, which may eventually inform future human clinical trials, thereby benefiting both sectors.
Significance of Veterinary Clinical Trials
The clinical trials under Ohio State University’s Blue Buffalo Veterinary Clinical Trials Office represent one of the largest initiatives of its kind in the country. They are pivotal for advancing veterinary knowledge and translating findings into human health breakthroughs. Dr. Adam Rudinsky, an associate professor at the university, emphasizes the importance of such trials in improving outcomes for both pets and their owners, stating that these valuable insights could lead to revolutionary treatments.
About Lamassu Biotech
Lamassu Biotech is well known for its commitment to addressing severe and unmet medical needs. This collaboration showcases their dedication to innovation in the pharmaceutical space. Their recent developments in RABI-767, conducted with prestigious organizations like the Mayo Clinic, have already indicated potential benefits in minimizing complications caused by acute pancreatitis.
RABI-767 is designed to reduce mortality and improve the quality of life for those afflicted with severe acute pancreatitis. The focus on an injection delivered directly around the pancreas seeks to lessen symptoms, reduce complications, and safeguard against organ failure—crucial steps in improving treatment protocols.
Moreover, the strategic partnership with Arrivo Bioventure focuses on advancing human clinical trials, promoting a comprehensive approach to tackling this condition. With a determined vision, Lamassu Biotech aims to expedite the availability of RABI-767 for both pets and people, reinforcing their mission to foster hope and healing.
Frequently Asked Questions
What is the focus of the collaboration between Lamassu Biotech and The Ohio State University?
The collaboration aims to advance the development of RABI-767, a novel therapeutic treatment for acute pancreatitis affecting both humans and dogs.
How does acute pancreatitis impact dogs and humans?
Acute pancreatitis is a serious health issue that can lead to hospital admissions and, in severe cases, can be life-threatening. It affects both humans and canines, highlighting the urgent need for effective treatments.
What are the expected outcomes of the veterinary clinical trials?
The trials aim to evaluate the efficacy of RABI-767 in treating spontaneous canine acute pancreatitis, which could refine dosing strategies for future human trials.
Who is leading the research at Lamassu Biotech?
Dr. Gabi Hanna, the CEO and founder of Lamassu Biotech, leads the company’s innovative efforts in developing treatments for severe medical conditions.
What is the ultimate goal of Lamassu Biotech's research efforts?
The ultimate goal is to bring effective treatments quickly to both pets and people, improving outcomes and quality of life for those affected by acute pancreatitis.
